NEW YORK (GenomeWeb News) – Roche said Monday that it will distribute two cancer mutation tests for the UK molecular diagnostics company DxS.
DxS makes companion diagnostics that can be used by oncologists to aid in the prognosis and development of treatments for cancer patients based on specific gene mutations, Roche said.
Roche will distribute the TheraScreen K-RAS Mutation Test, which detects seven mutations found in many cancer types and is used in colorectal cancer cases, through a worldwide, exclusive agreement.
The second test involved in the agreement, the TheraScreen EGFR 29 Mutation Test, detects mutations that correlate with responsiveness to EGFR tyrosine kinase inhibitors. This test may be used to help doctors choose lung cancer patients who are most likely to respond to treatment with EGFR tyrosine kinase inhibitors.
Roche has agreed to distribute this test exclusively to all global markets except the US, Canada, Mexico, and Hong Kong. Both of the companion tests have received European CE mark certification.
Financial terms of the agreement were not released.